MikroScore
Transparent product review

Product Review

Dihydroberberine (GlucoVantage) 200 mg

Various · Capsule · 200 mg

Price/day

€0.50

Dose

200 mg

Servings/pack

60

Pack price

€29.90

Transparency Index

7.4/10

Recommended Next-generation berberine — higher bioavailability at a lower dose, with fewer GI side effects than standard berberine.

Rating breakdown

Evidence for ingredient 7.0/10

Berberine has good evidence for blood sugar and lipid management. Dihydroberberine is the active metabolite with better absorption, but fewer independent studies.

Value for money 6.0/10

€0.50 per day for 200 mg DHB is pricier than standard berberine, but the 5× bioavailability puts it in context.

Product quality 8.0/10

GlucoVantage is a patented, clinically tested ingredient. 200 mg DHB ≈ 1000 mg standard berberine.

Label honesty 8.0/10

GlucoVantage branded ingredient named, dihydroberberine explained as the metabolite form.

Third-party testing 7.0/10

GlucoVantage is patented and analytically characterized. End-product testing varies by brand.

Product Description

Dihydroberberine (DHB) is the active metabolite that berberine is converted into in the gut. GlucoVantage bypasses this step by delivering DHB directly — with up to 5× higher bioavailability at a lower dose. 200 mg DHB is considered equivalent to 1000–1500 mg standard berberine.

What We Like

  • 5× higher bioavailability than standard berberine
  • Lower dose needed (200 mg instead of 1000+ mg)
  • Significantly fewer gastrointestinal side effects
  • GlucoVantage is a patented, clinically validated ingredient

What We’re Missing

  • Less direct study evidence than standard berberine (most RCTs use berberine HCl)
  • Higher daily cost than standard berberine
  • Multiple brands use GlucoVantage — end-product quality varies
  • Long-term safety data specific to DHB is still limited

Usage Recommendation

1 capsule (200 mg) 1–2× daily with a meal. Do not combine with metformin without medical advice (both lower blood sugar).

Ingredient dossier

Berberine shows clinically relevant blood glucose and LDL effects in RCTs for type 2 diabetes. Significant drug interactions and unclear EU regulatory status require caution.

Read full dossier: Berberine →